Drug Trial Radar · NCT01173939
Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments
Last checked: Nov 20, 2026Latest source record: Jun 1, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10,000
Planned (sponsor's estimate)
Start
Jul 2010
Primary completion
Jun 2014
Sponsor
- Lead sponsor
- Positive Trial GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 2, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to compare the effect of standard treatment (target LDL-C level: \<120 mg/dL (JASGL 2007 target level)) and intensive treatment (target LDL-C level: \<70 mg/dL) in the prevention of major adverse cardiac events (MACE) in hypercholesterolemia patients with concomitant type 2 diabetes and hypertension.
Conditions
- Hypercholesterolemia
- Type 2 Diabetes
- Hypertension
Interventions
PravastatinDrug
5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
RosuvastatinDrug
5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of \<70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: At baseline
- MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 1 month after treatment initiation
- MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 3 month after treatment initiation
- MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 6 month after treatment initiation
- MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 12 month after treatment initiation
- MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: 36 month after treatment initiation
- MACE (time to event): MACE (time to event): myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal/nonfatal cerebrovascular accident, peripheral arteriopathy, aortic eventTime frame: At the end of the study or discontinuation up to 4 years
Locations
317 sites in 1 country. Site status is shown where the registry gives one.
Fukushi Clinic
Aomori, Japan
Kashiwagi Clinic
Ayase, Japan
Hayashi Diabetes Clinic
Chigasaki, Japan
Uchiyama Clinic
Jōetsu, Japan
Nitta Medical Clinic
Kamiinagun, Japan
Imai Clinic
Kawasaki, Japan
Tani Clinic
Kitakyushu, Japan
Marumo Clinic
Koganei, Japan
Ihara Clinic
Kyoto, Japan
Goko-Hospital
Matsudo, Japan
Satou Clinic
Mooka, Japan
Iino Clinic
Nirasaki, Japan
Miura Clinic
Osaka, Japan
Kuroda Iin
Ōtsuki, Japan
Sasaki Clinic
Sendai, Japan
Kamata Clinic of Internal Medicine
Shiki, Japan
Nishikawa Clinic
Shimoda, Japan
Satou Iin
Shimoinagun, Japan
Kumagai Clinic
Shinshiro, Japan
Suzuki Clinic
Toyokawa, Japan
Benibana Clinic
Yamagata, Japan
Fujimi Clinic
Yokohama, Japan
Hongo Clinic
Yokohama, Japan
Jiyukai Yamada Naika
Yokohama, Japan
Shonan Ochanomizu Clinic
Yokohama, Japan
Tani Clinic Internal Medicine, Allergology & Rheumatology
Yokohama, Japan
Hiramitsu Heart Clinic
Nagoya, Aichi Pref., Japan
Medical Dock&Clinic
Nagoya, Aichi Pref., Japan
Matsuno Medical Clinic
Iyo Gun, Ehime Pref., Japan
Ishite Matsumoto Naika Junkanki Clinic
Matsuyama, Ehime Pref., Japan
Ehime Medical CO-OP Izumigawa Clinic
Niihama, Ehime Pref., Japan
Tsugawa Internal Medicine Clinic
Echizen, Fukui Pref., Japan
Fukui Chuo Clinic
Fukui, Fukui Pref., Japan
Koshino Clinic
Sakai, Fukui Pref., Japan
Fukuoka University Chikushi Hospital
Chikushino-shi, Fukuoka Pref., Japan
Saiseikai Futsukaichi Hospital
Chikushino-shi, Fukuoka Pref., Japan
Abies Clinic
Fukuoka, Fukuoka Pref., Japan
Hirano Medical Clinic
Fukuoka, Fukuoka Pref., Japan
Naitoh Clinic
Fukuoka, Fukuoka Pref., Japan
Saku Hospital
Fukuoka, Fukuoka Pref., Japan
Showing 40 of 317 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.